T. Rowe Price Investment Management’s Allogene Therapeutics ALLO Stock Holding History

T. Rowe Price Investment Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49K	Buy	+23,151	New	+$50.8K	﹤0.01%	738

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

T. Rowe Price Investment Management's ALLO Position: Q2 2026 in Review

T. Rowe Price Investment Management opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 23,151 shares worth $49K. The stake represents ﹤0.01% of the portfolio and ranks #738 among its holdings.

209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

T. Rowe Price Investment Management held 23,151 shares of Allogene Therapeutics worth $49K as of Q2 2026.
Allogene Therapeutics was a new T. Rowe Price Investment Management position in Q2 2026.
Allogene Therapeutics made up ﹤0.01% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #738 holding.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.